Research Roundup


20191453 - idea concept with light bulbs and energy save bulb green background

Debbie Rigby rounds up the latest in research news

Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women’s Health Initiative

Analysis of data from the Women’s Health Initiative shows 10 to 13 years of bisphosphonate use is associated with a 29% higher risk of any clinical fracture than 2 years of use in older women. However the association was not statistically significant for hip, clinical vertebral, or wrist fractures. On average participants were 80 years old and were followed for 3.7 ± 1.2 years.

J Am Geriatr Soc 2017;65:In press

Editorial

 

Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality

A systematic review and network meta-analysis of 42 trials, including 144,220 patients, suggests that reducing SBP to levels below currently recommended targets significantly reduces the risk of cardiovascular disease and all-cause mortality. These findings support more intensive control of SBP among adults with hypertension.

JAMA Cardiol. Published online May 31, 2017.

 

Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis

The 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis recommends treating only with calcium and vitamin D in adults at low fracture risk, and treating adults at moderate-to-high fracture risk with calcium and vitamin D plus an additional osteoporosis medication (oral  bisphosphonate preferred). The guidelines also make recommendations for special populations, including children, people with organ transplants, women of childbearing potential, and people receiving very high-dose glucocorticoid treatment.

Arthritis & Rheumatology 2017

 

Incretin based treatments and mortality in patients with type 2 diabetes

A systematic review and meta-analysis of randomised trials has concluded that incretin based treatments, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, do not increase all cause mortality in patients with type 2 diabetes.

BMJ 2017;357:j2499

Previous Forum: Codeine Upscheduling
Next Interim report 'a step backwards'

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply